Renal safety and angiotensin II blockade medications in patients undergoing non-emergent coronary angiography: a randomized controlled study.

What Was Tested

Researchers studied Angiotensin-Converting Enzyme Inhibitors in this randomized controlled trial publication.

To evaluate in a randomized controlled trial whether uninterrupted administration of angiotensin II (AnglI) blockade medications influence estimated glomerular filtration rate (eGFR) in patients undergoing non-emergent coronary angiography.

Why It Was Studied

Contrast-induced nephropathy (CIN) is one of the major causes of new-onset renal failure in hospitalized patients.

Although renin-angiotensin-aldosterone system (RAAS) blocking agents are widely used among patients requiring contrast studies, data on the effect of these agents on the development of CIN are sparse and inconsistent.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

Patients receiving treatment with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACE-I/ARB) were recruited consecutively.

The enrolled subjects were randomized into three groups at a 1:1:1 ratio: group A (ACE/ARB stopped 24 hours prior to the procedure and restarted immediately after the procedure), group B (ACE/ARB stopped 24 hours prior to the procedure and restarted 24 hours after the procedure), and group C (ACE/ARB continued throughout the study period).

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Angiotensin-Converting Enzyme Inhibitors and who got the comparison, which limits bias.

Plasma creatinine was measured and eGFR was calculated according to the Cockroft-Gault equation before and 48 hours after the coronary angiography.

The primary endpoint was a change in eGFR at 48 hours.

What Was Measured

PubMed files the paper under topics including Angiotensin II Type 1 Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Contrast Media, Coronary Angiography, Creatinine, Glomerular Filtration Rate and Kidney Diseases.

What This Means in Plain Language

The paper is a randomized study of Angiotensin-Converting Enzyme Inhibitors.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2013 (The Israel Medical Association journal : IMAJ), a journal based in Israel.

More context: all human trials.